PRX抗体—艾普蒂

PRX antibodies target peroxiredoxin (PRX) proteins, a highly conserved family of antioxidant enzymes critical for regulating cellular redox homeostasis. First identified in the 1980s, PRX proteins are classified into six subtypes (PRX1-6) that catalyze the reduction of peroxides, protecting cells from oxidative damage caused by reactive oxygen species (ROS). Beyond their antioxidant role, PRXs participate in signaling pathways, immune response modulation, and apoptosis regulation. Dysregulation of PRX expression or activity is linked to cancer, neurodegenerative diseases, diabetes, and inflammatory disorders. For example, PRX1/2 are overexpressed in multiple cancers, correlating with tumor progression and therapy resistance, while PRX3/4 are associated with mitochondrial function and apoptosis. PRX antibodies are essential tools in biomedical research, enabling detection of PRX isoforms in tissues, cell lines, or biological fluids via techniques like Western blot, immunohistochemistry, and ELISA. They also aid in studying PRX interactions, post-translational modifications (e.g., hyperoxidation), and subcellular localization. Some therapeutic applications explore PRX antibodies for targeted cancer therapies or as biomarkers for oxidative stress-related diseases. Species-specific PRX antibodies (human, mouse, rat) facilitate cross-disciplinary studies, though challenges remain in isoform specificity due to structural similarities. Ongoing research continues to unravel PRX roles in disease mechanisms and their potential as diagnostic or therapeutic targets.